View of Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data | Acta Oncologica

Return to Article Details Pembrolizumab as first-line treatment for recurrent and metastatic head and neck cancer – real-world single-centre data